Hypertriglyceridemia Therapeutics Market, by Type (Primary and Secondary), by Drug Class (Statins, Fibrates, Niacin, Omega-3 Fatty Acids, and HMG-CoA Reductase inhibitors), by Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, and

Hypertriglyceridemia Therapeutics Market, by Type (Primary and Secondary), by Drug Class (Statins, Fibrates, Niacin, Omega-3 Fatty Acids, and HMG-CoA Reductase inhibitors), by Distribution Channel (Online Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Hypertriglyceridemia is a condition and common disorder in which the triglyceride levels in the body increase. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body.
Market Dynamics
The ongoing research and development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. For instance, in March 2021, Arrowhead Pharmaceuticals initiated a phase I study of ‘ARO-APOC3’ for the treatment of hypertriglyceridemia. ARO-APOC3 is the company’s second cardio metabolic candidate entering clinical trials, following ARO-ANG3 for the treatment of metabolic diseases and dyslipidemias. Moreover, the growing prevalence of atherosclerosis and other cardiovascular diseases are fueling the market growth. For instance, according to the WHO, about 17.9 million deaths were reported in 2016 due to cardiovascular diseases.
Approvals of drugs and product launches are also expected to create growth opportunities for players operating in the global hypertriglyceridemia market. However, the high costs associated with the treatment and medical care in emerging economies is expected to hinder the market growth in the coming years.
Key features of the study:
This report provides in-depth analysis of the global hypertriglyceridemia market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hypertriglyceridemia market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are Biocon, Sanofi, Novo Nordisk A/S, GlaxoSmithKline Plc, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, Inc, Wockhardt, Julphar, Pfizer, Inc., Eli Lilly and Company, Adocia, Bristol-Myers Squibb Company, Hikma Pharmaceutical PLC, AbbVie Inc., Lupin Ltd., Accord Healthcare, Zydus Pharmaceuticals Inc., Amneal pharmaceutical LLC, Glenmark, and Aurobindo Pharma.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hypertriglyceridemia market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hypertriglyceridemia market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Hypertriglyceridemia Market, By Type:
Primary
Secondary
Global Hypertriglyceridemia Market, By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
Global Hypertriglyceridemia Market, By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Global Hypertriglyceridemia Market, By Region:
North America
By Country:
U.S.
Canada
By Type:
Primary
Secondary
By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Type:
Primary
Secondary
By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Type:
Primary
Secondary
By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Type:
Primary
Secondary
By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Type:
Primary
Secondary
By Drug Class:
Statins
Fibrates
Niacin
Omega-3 Fatty Acids
HMG-CoA Reductase inhibitors
By Distribution Channel:
Online Pharmacy
Retail Pharmacy
Hospital Pharmacy
Others
Company Profiles
Biocon
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Sanofi
Novo Nordisk A/S
GlaxoSmithKline Plc
Tonghua Dongbao Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Oramed Pharmaceuticals, Inc
Wockhardt
Julphar
Pfizer, Inc.
Eli Lilly and Company
Adocia
Bristol-Myers Squibb Company
Hikma Pharmaceutical PLC
AbbVie Inc.
Lupin Ltd.
Accord Healthcare
Zydus Pharmaceuticals Inc.
Amneal pharmaceutical LLC
Glenmark
Aurobindo Pharma
“*” marked represents similar segmentation in other categories in the respective section.